Professor Graham Jenkin |
"Specifically designed to underpin clinical
translation of cell therapies and regenerative medicine, the establishment of
the Cell Therapies Platform is a major new initiative within the
precinct," said Professor Graham Jenkin of Monash University’s Department
of Obstetrics and Gynaecology and Deputy Director of The Ritchie Centre, Hudson
Institute of Medical Research.
"We've built this Platform in response to
the under-supply of affordable cleanroom facilities in Victoria for clinical
translation of our research, particularly for the manufacture of
biologicals."
The facility will host a Biospherix Xivo GMP
cell isolator, a state of the art, MACSQuant® Tyto™ GMP Cell Sorter and a
multipurpose GenSim, Bioscaffolder/Bioprinter with stem cell bioprinting
capability.
"The Cell Therapies Platform will play a
vital role in accelerating translational research leading to the development of
new treatments for diseases such as Bronchopulmonary dysplasia of the premature
newborn, cerebral palsy, cancer, and tissue replacement with biomimetic
materials.
Professor Jenkin said the Platform offers an integrated,
fully contained Good Manufacturing Practice (GMP) environment that is a
flexible, cost-effective alternative to conventional cleanroom
facilities.
"This will become a core facility of the
Victorian Consortium for Cell-based Therapies and will underpin pre-clinical
and early phase clinical manufacture of tissues and cells for small to medium
scale clinical trials and therapies," said Professor Jenkin.
Miltenyi Biotec, the manufacturer of the GMP
Gradde cell sorter, has granted prestigious Early Adopter Program status to the
Cell Therapies Platform for installation and support of the Miltenyi cell
sorter and will establish a Miltenyi Biotec Cell Therapy Centre of Excellence
within the MHTP to assist and support translation of potential cell therapies
to clinical trials.
The establishment of the Cell Therapies Platform
has been made possible by the generous support of Therapeutic Innovations
Australia, through the Translating Health Discovery Program of the National
Collaborative Research Infrastructure Strategy Program, The Ian
Potter Foundation and Miltenyi Biotec.
No comments:
Post a Comment